Bringing Cure...Building Hope...
Home | Blog | Events
Pharma legitimate consultant and facilitator in Delhi India

KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval: {YYYY} Available In India

KADCYLA (ado-trastuzumab emtansine) for injection is a prescription medicine. KADCYLA (ado-trastuzumab emtansine) for injection is used to treat Ovarian cancer and breast cancer. Brand KADCYLA (ado-trastuzumab emtansine) for injection Can be imported and made available on "Patient Name basis" treatment in India. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.

Generic Name: ado-trastuzumab emtansine. Brand Name: KADCYLA.
KADCYLA (ado-trastuzumab emtansine) for injection
is a prescription medicine used for the treatment of patients with treatment of adult patients with HER2-positive, metastatic breast cancer

Therapeutic indications and Usage KADCYLA is a prescription medicine. KADCYLA is used to treat HER2-positive breast cancer KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane,separately or in combination. Patients should have either: • Received prior therapy for metastatic disease, or • Developed disease recurrence during or within six months of completing adjuvant therapy.

Active ingredient: (ado-trastuzumab emtansine) For Injection
DISEASE INDICATIONS: Breast Cancer
MANUFACTURER : Genentech
DOSAGE FORM & STRENGTHS: Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.
MEDICINE APPROVED BY: European Medical Agency (EMA), Food and Drug Administration (FDA)
Source Details: Patient Information

Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "KADCYLA (ado-trastuzumab emtansine) for injection" in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Healthcare Professional In India If you have any question, please email IPN Support Team or Call Indian Pharma Network for KADCYLA (ado-trastuzumab emtansine) for injection price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774

Indian Pharma Network, New Delhi. India

IPN, Delhi are legitimate consultant and facilitator in India, group of highly qualified pharma professionals.
Specialized in Oncology and other pharma products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Mumbai | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur | Punjab | Chandigarh
Our Overseas Network Uk | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

KADCYLA (ado-trastuzumab emtansine)injection
Note:-

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Facts of KADCYLA (ado-trastuzumab emtansine) for injection

IBRANCE is a prescription medicine used in adults to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) in combination with: • an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men, or • fulvestrant with disease progression following hormonal therapy. It is not known if IBRANCE is safe and effective in children.

Active ingredient: ado-trastuzumab emtansine Inactive ingredients: microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard gelatin capsule shells. The light orange, light orange/caramel and caramel opaque capsule shells contain: gelatin, red iron oxide, yellow iron oxide, and titanium dioxide
Source content : www.accessdata.fda.gov

IPN, New Delhi can facilitate patient to import of "KADCYLA (ado-trastuzumab emtansine) for injection" in small quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of KADCYLA (ado-trastuzumab emtansine) injection in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the KADCYLA (ado-trastuzumab emtansine) injection medicine cost price in India.

The order for KADCYLA (ado-trastuzumab emtansine) injection will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of KADCYLA (ado-trastuzumab emtansine) from authorised distributor.

The pharmacokinetics of KADCYLA was evaluated in a phase 1 study and in a population 472 pharmacokinetic analysis for the ado-trastuzumab emtansine conjugate (ADC) using pooled data from 5 trials in patients with breast cancer. A linear two-compartment model with first-order elimination from the central compartment adequately describes the ADC concentration-time profile. In addition to ADC, the pharmacokinetics of total antibody (conjugated and unconjugated trastuzumab), DM1 were also determined.

KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval: {YYYY}

Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial..

For KADCYLA (ado-trastuzumab emtansine) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

ADC ARX788 Gets Fast Track Status for HER2+ Metastatic Breast Cancer For More Details

Kadcyla approved for post-surgical use in Japan. ReadMore

Step 1. Send a request for your medicine online:- Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Step 2. Verification of documents:- We verify your a prescription and necessary documents to import drugs in small quantities for personal use.

Step 3. Permission to Import:- After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.

Step 4. We source your medicine:- Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 5. Delivery of medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find out -
KADCYLA (ado-trastuzumab emtansine) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
KADCYLA (ado-trastuzumab emtansine) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
KADCYLA (ado-trastuzumab emtansine) price in North America – Mexico.
KADCYLA (ado-trastuzumab emtansine) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
KADCYLA (ado-trastuzumab emtansine) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
KADCYLA (ado-trastuzumab emtansine) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
KADCYLA (ado-trastuzumab emtansine) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
KADCYLA (ado-trastuzumab emtansine) price in Australia and New Zealand.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

Get Access To KADCYLA (ado-trastuzumab emtansine) for injection

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in breast cancer treatment. Brand Name "KADCYLA (ado-trastuzumab emtansine) for injection" or Generic Name "ado-trastuzumab emtansine for Injection" can be imported for personal use under "patient name basis" treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim India. Contact us at urgent@indianpharmanetwork.co.in or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.